Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2- aminopropane in rhesus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 2, 2008, Pages 827-833

  Li, Jun Xu ^a   Rice, Kenner C ^b   France, Charles P ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIMETHOXY 4 METHYLAMPHETAMINE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; AMPHETAMINE; COCAINE; FENFLURAMINE; HALOPERIDOL; KETAMINE; KETANSERIN; LYSERGIDE; MDL 100009; METHAMPHETAMINE; MORPHINE; PHENCYCLIDINE; PSYCHEDELIC AGENT; QUIPAZINE; RITANSERIN; SALVINORIN A; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; VOLINANSERIN; YOHIMBAN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DISCRIMINATION; DRUG EFFECT; FEMALE; HALLUCINATION; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; STIMULUS RESPONSE;

2,5-DIMETHOXY-4-METHYLAMPHETAMINE; ANIMALS; DISCRIMINATION LEARNING; FEMALE; MACACA MULATTA; MALE; REACTION TIME;

EID: 38749134465     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.130625     Document Type: Article

References (41)

1. Arasteh K, Poudevida S, Farre M, Roset PN, and Cami J (1999) Response patterns of the Spanish version of the 49-item short form of the Addiction Research Center Inventory after the use of sedatives, stimulants and opioids. Drug Alcohol Depend 55:117-125.
2. Arvanov VL and Wang RY (1998) M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl- D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 18:197-209.
3. Barrett JE and Gleeson S (1992) Discriminative stimulus effects of 8-OH-DPAT in pigeons: antagonism studies with the putative 5-HT1A receptor antagonists BMY7378 and NAN-190. Eur J Pharmacol 217:163-171.
4. Bergman J, Rosenzweig-Lipson S, and Spealman RD (1995) Differential effects of dopamine D1and D2 receptor agonists on schedule-controlled behavior of squirrel monkeys. J Pharmacol Exp Ther 273:40-48.
5. Butelman ER, Harris TJ, and Kreek MJ (2004) The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl) 172:220-224.
6. Colpaert FC (1984) Cross generalization with LSD and yohimbine in the rat. Eur J Pharmacol 102:541-544.
7. Cunningham KA, Callahan PM, and Appel JB (1987) Discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OHDPAT): implications for understanding the actions of novel anxiolytics. Eur J Pharmacol 138:29-36.
8. Cunningham KA and Appel JB (1987) Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD). Psychopharmacology (Berl) 91:67-73.
9. Eckler JR, Greizerstein H, Rabin RA, and Winter JC (2001) A sensitive method for determining levels of [-]-2,5,-dimethoxy-4-methylamphetamine in the brain tissue. J Pharmacol Toxicol Methods 46:37-43.
10. Fantegrossi WE, Harrington AW, Eckler JR, Arshad S, Rabin RA, Winter JC, Coop A, Rice KC, and Woods JH (2005) Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl) 181:496-503.
11. Fiorella D, Rabin RA, and Winter JC (1995a) Role of 5-HT2A and 5-HT2C receptors in the Stimulus effects of hallucinogenic drugs. II: reassessment of LSD false positives. Psychopharmacology (Berl) 121:357-363.
12. Fiorella D, Helsley S, Rabin RA, and Winter JC (1995b) The interactions of typical and atypical antipsychotics with the (-)2,5,-dimethoxy-4- methamphetamine (DOM) discriminative stimulus. Neuropharmacology 34:1297-1303.
13. Gerak LR and France CP (1996) Discriminative stimulus effects of nalbuphine in rhesus monkeys. J Pharmacol Exp Ther 276:523-531.
14. Glennon RA, Young R, and Rosecrans JA (1983a) Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur J Pharmacol 91:189-196.
15. Glennon RA, Rosecrans JA, and Young R (1983b) Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents. Med Res Rev 3:289-340.
16. Glennon RA and Hauck AE (1985) Mechanistic studies on DOM as a discriminative stimulus. Pharmacol Biochem Behav 23:937-941.
17. Glennon RA (1988) Site-selective serotonin agonists as discriminative stimuli. Psychopharmacol Ser 4:15-31.
18. Gonzalez D, Riba J, Bouso JC, Gomez-Jarabo G, and Barbanoj MJ (2006) Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 85:157-162.
19. Gründer G, Yokoi F, Offord SJ, Ravert HT, Dannals RF, Salzmann JK, Szymanski S, Wilson PD, Howard DR, and Wong DF (1997) Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology 17:175-185.
20. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
21. Jackson A, Koek W, and Colpaert FC (1992) NMDA antagonists make learning and recall state-dependent. Behav Pharmacol, 3:415-421.
22. Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, et al. (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277:968-981.
23. Kleven MS and Koek W (1998) Discriminative stimulus effects of 8-hydroxy-2-(di-n-propylamino) tetralin in pigeons and rats: species similarities and differences. J Pharmacol Exp Ther 284:238-249.
24. Koek W, Woods JH, Jacobson AE, Rice KC, and Lessor RA (1986) Metaphit, a proposed phencyclidine receptor acylator: phencyclidine-like behavioral effects and evidence of absence of antagonist activity in pigeons and in rhesus monkeys. J Pharmacol Exp Ther 237:386-392.
25. Nielsen EB (1985) Discriminative stimulus properties of lysergic acid diethylamide in the monkey. J Pharmacol Exp Ther 234:244-249.
26. Rabin RA, Doat M, and Winter JC (2000) Role of serotonergic 5-HT2A receptors in the psychotomimetic actions of phencyclidine. Int J Neuropsychopharmacol 3:333-338.
27. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, and Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A. 99:11934-11939.
28. Rowlett JK and Woolverton WL (1997) Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: I. Comparison with triazolam in rhesus monkeys and rats. J Pharmacol Exp Ther 280:162-173.
29. Rush CR, Madakasira S, Goldman NH, Woolverton WL, and Rowlett JK (1997) Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: II. Comparison with triazolam and caffeine in humans. J Pharmacol ExpTher 280:174-188.
30. Schifano F, Deluca P, Agosti L, Martinotti G, Corkery JM, Alex B, Caterina B, Heikki B, Raffaella B, Anna C, et al. (2005) New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ('Blue Mystic'). J Psychopharmacol 19:675-679.
31. Schreiber R, Brocco M, and Millan MJ (1994) Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. Eur J Pharmacol 264:99-102.
32. Shulgin AT and Shulgin A (1991) PiHKAL: A Chemical Love Story. p. 633-637, Transform Press, Berkeley, CA.
33. Siebert DJ (1994) Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 43:53-56.
34. Silverman PB and Ho BT (1980) The discriminative stimulus properties of 2,5-dimethoxy-4-methylamphetamine (DOM): differentiation from amphetamine. Psychopharmacology (Berl) 68:209-215.
35. Smith RL, Barrett RJ, and Sanders-Bush E (2003) Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(±)DOI] in C57BL/6J mice. Psychopharmacology (Berl) 166:61-68.
36. Titeler M, Lyon RA, and Glennon RA (1988) Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl) 94:213-216.
37. Weerts EM, Fantegrossi WE, and Goodwin AK (2007) The value of nonhuman primates in drug abuse research. Exp Clin Psychopharmacol 15:309-327.
38. Winter JC (1980) Effects of the phenethylamine derivatives, BL-3912, fenfluramine, and Sch-12579, in rats trained with LSD as a discriminative stimulus. Psychopharmacology (Berl) 68:159-162.
39. Winter JC, Fiorella DJ, Timineri DM, Filipink RA, Helsley SE, and Rabin RA (1999) Serotonin receptor subtypes and hallucinogen-induced stimulus control. Pharmacol Biochem Behav 64:283-93.
40. Winter JC, Doat M, and Rabin RA (2000) Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists: a link between the glutamatergic and serotonergic hypotheses of schizophrenia. Life Sci 68:337-344.
41. Woolverton WL and English JA (1997) Effects of some phenethylamines in rhesus monkeys trained to discriminate (+)-amphetamine from saline. Drug Alcohol Depend 44:79-85.